


CompuFile Survey January 2004

Source:



COMPUFILE Limited

1 Tannery House, Tannery Lane, Send, Woking, Surrey, GU23 7EF
Telephone: 01483 222848 Fax: 01483 211037

CompuFile Survey
January 2004

In January 2004, POZEN commissioned CompuFile Ltd to perform a quantitative assessment of the prescribing patterns of UK general practitioners (GP) who treat patients with migraine. The data were obtained from the DIN-LINK longitudinal database. DIN-LINK is a UK longitudinal patient database, sourced from the medical records of almost 2,000,000 patients collected *in-situ* via GP practice software. The data collected for each patient include the following, where recorded by the GP: symptoms and diagnosed conditions; prescriptions issued for each condition (including form and dose instructions); investigations and test results; and referral details. A subgroup of 392 GPs was selected as having the highest-quality data and the best national representation. A diagnostic note of migraine was required in the patient's medical record, except in the case of triptans since there is no other indication for this medication. The database was queried for the past 5 years and data reported up to November 2003 were included. Each of 10 UK health authorities was represented by from 20 to 55 GPs which made up the GP subgroup. From the actual numbers of patients with migraine treated, projections were made for the entire UK population. The data for the 60 months ending November 2003 are shown here.

	<u>Nov 1999*</u>	<u>Nov 2000*</u>	<u>Nov 2001*</u>	<u>Nov 2002*</u>	<u>Nov 2003*</u>
Patients treated for migraine (UK)**	1,019,301	1,049,278	1,038,755	1,050,565	1,029,596
Triptans	296,971	323,315	345,571	370,552	377,592
Non-narcotic analgesics	395,305	400,529	393,489	388,190	375,245
NSAIDs	148,145	167,221	165,405	171,461	178,122
Other agents	239,288	232,853	220,287	212,414	201,135
Mig/anti-emetic comb	112,717	101,968	96,896	86,525	79,031
Patients treated with fixed combinations					
Paracetamol + metoclopramide (Paramax)	108,554	95,912	88,645	79,636	69,493
Aspirin + metoclopramide (MigraMax)		1,060	5,980	4,769	5,450

- * Sub-segments may add to more than the total as some patients may be included in more than one sub-segment.
- ** Total patients under GP care treated for migraine, projected for the UK.
- *** For patients who received Paramax, the most common dosage prescribed (two 5 mg tablets or sachets three times per day) provided 30 mg per day of metoclopramide (43,755 patients in 2003). The most common dosage of domperidone as a single agent was 21-30 mg/day (5,753 patients in 2003).

View Name: Migraine adhoc
DIN-LINK Report: Migraine adhoc - Report AH

Report Data: Patients

Patient type: All patients
Co-therapy: w/wo anti-emetics
Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
Acute migraine market	1,019,301	1,049,278	1,038,755	1,050,565	1,029,596
Triptans	296,971	323,315	345,571	370,552	377,592
Non-narcotic analges	395,305	400,529	393,489	388,190	375,245
Systemic NSAIDS	148,145	167,221	165,405	171,461	178,122
Other agents	239,288	232,853	220,287	212,414	201,135
Mig/anti-emetic comb	112,717	101,968	96,896	86,525	79,031

View Name: Migraine adhoc
DIN-LINK Report: Migraine adhoc - Report AH

Report Data: Rxs

Patient type: All patients
Co-therapy: w/wo anti-emetics
Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
Acute migraine market	3,880,930	4,092,495	4,192,455	4,356,250	4,334,490
Triptans	1,388,475	1,530,425	1,656,990	1,794,010	1,829,455
Non-narcotic analges	1,219,240	1,280,440	1,259,360	1,271,770	1,234,455
Systemic NSAIDS	282,625	316,965	325,550	357,425	378,250
Other agents	785,485	777,070	774,265	766,870	736,950
Mig/anti-emetic comb	205,105	187,595	176,290	166,175	155,380

View Name: Migraine adhoc
DIN-LINK Report: Migraine adhoc - Report AH

Report Data: Doses

Patient type: All patients
Co-therapy: w/wo anti-emetics
Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
Acute migraine market	184,107,536	192,407,024	190,807,664	196,371,840	193,652,864
Triptans	9,687,280	10,954,035	12,153,300	13,592,775	14,276,430
Non-narcotic analges	106,490,552	114,030,472	112,307,272	115,008,312	110,956,280
Systemic NSAIDS	16,368,620	17,676,770	18,502,290	20,063,316	21,933,400
Other agents	41,749,620	40,953,512	40,204,152	40,301,984	39,641,112
Mig/anti-emetic comb	9,811,465	8,792,230	7,640,650	7,405,455	6,845,645

View Name: Migraine adhoc
DIN-LINK Report: Migraine adhoc - Report AH

Report Data: Patients
Patient type: All patients
Co-therapy: w/wo anti-emetics
Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
Acute migraine market	1,018,619	1,048,142	1,037,014	1,048,672	1,028,233
Suppositories	2,195	2,120	1,741	1,514	1,211
Nasal	10,674	13,777	13,702	15,367	19,985
Injectable	14,989	16,200	15,821	15,897	15,519
Oral	1,008,173	1,034,592	1,024,297	1,035,803	1,013,017
Inhalers	1,287	454	76		

View Name: Migraine adhoc
DIN-LINK Report: Migraine adhoc - Report AH

Report Data: Rx's
Patient type: All patients
Co-therapy: w/wo anti-emetics
Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
Acute migraine market	3,877,445	4,085,865	4,185,315	4,347,410	4,325,395
Suppositories	9,860	9,520	6,800	7,480	6,460
Nasal	34,000	41,480	45,900	47,855	60,095
Injectable	92,395	100,640	96,560	93,840	86,020
Oral	3,751,050	3,943,745	4,042,855	4,205,715	4,179,280
Inhalers	1,700	595	85		

Key	
Black	Form/strength
Red	Daily dose
Blue	Dosing regimen

Report Data: Patients
Products: Acute migraine market
 Patient type: All patients
 Age/gender: All patients

Projection - Patients = 75.7, Scripts = 85, GPs = 100

	MAT Nov 1999	MAT Nov 2000	MAT Nov 2001	MAT Nov 2002	MAT Nov 2003
w/wo anti-emetics	1,019,301	1,049,278	1,038,755	1,050,565	1,029,596
Ref. anti-emetics	141,256	134,519	125,359	117,562	106,813
Plain anti-emetics	27,933	32,475	28,312	30,810	28,615
metoclopramide (t)	17,790	21,272	16,881	18,395	16,427
meto hcl 5mg tabs	151	379	454	530	303
meto 10mg tablets	15,973	18,622	15,216	16,351	14,913
meto 15mg m/r tab	76	151		76	303
meto 15mg m/r cap			76	76	227
meto 30mg m/r cap	76	151			
meto 10mg/2ml inj	303	833	833	454	454
meto 100mg/20ml i				76	
meto 1mg/ml liqui					
meto 5mg/5ml elix	1,060	1,136	379	454	76
meto 5mg/5ml s/f	303	227	227	530	303
meto <=5/day					
meto 6-10/day	303	76	76	151	151
meto 11-15/day	227	303	76	303	151
meto 16-20/day	76	227	303	303	76
meto 21-29/day					
meto 30/day	13,475	15,973	12,642	14,156	12,793
meto >30/day	303	227	151	454	227
meto n/s	3,709	4,693	4,391	3,331	3,255
meto 5 tb 2od					
meto 5 tb 2bd					
meto 5 tb 2qds					
meto 5 tb tds		151	76	76	76
meto 10 od	227	76	76	151	151
meto 10 bd	76	227	303	227	76
meto 10 tds	13,172	15,443	12,566	13,929	12,339
meto cap 15 od					
meto cap 15 bd			76	76	227
meto tab 15 od					
meto tab 15 bd	76	151		76	303
Comb migraine/anti-	114,913	103,633	98,486	88,266	80,091
metoclop. comb	108,554	96,972	94,171	83,951	74,792
aspirin+metoclop		1,060	5,980	4,769	5,450
Migramax (b)		1,060	5,980	4,769	5,450
Migramax sachet		1,060	5,980	4,769	5,450
aspirin+metoclop					
aspirin+metoclo					
Migramax <=10/da					
Migramax 11-15/d					
Migramax 16-20/d					76
Migramax 21-29/d					
Migramax 30/day			151		151
Migramax >30/day			76		
Migramax n/s		1,060	5,753	4,769	5,223
Migramax tds			151		151
Paramax (t)	108,554	95,912	88,645	79,636	69,493
Paramax sachets	32,627	27,328	28,690	21,953	21,499
Paramax tablets	76,684	69,114	60,939	58,138	48,448
Paramax <=5/day	227	227	151	151	151
Paramax 6-10/day		76	227	151	76
Paramax 11-15/da	3,936	3,104	3,785	2,650	2,044
Paramax 16-20/da	454	379	379	151	303
Paramax 21-29/da					
Paramax 30/day	65,708	60,863	55,034	52,612	43,755
Paramax >30/day	303	303	379	379	379
Paramax n/s	39,061	31,845	29,977	24,224	23,331
Paramax 5 od	227	227	151	151	151
Paramax 5 bd		76	151	76	76
Paramax 5 tds	3,936	3,104	3,785	2,650	2,044
Paramax 5 qds	379	227	151	151	76
Paramax 5 2od			76	76	
Paramax 5 2bd	76	151	227		227
Paramax 5 2tds	65,632	60,636	54,883	52,536	43,755
Paramax 5 2qds	151	151	76	76	151